Business
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.\n\n“The goal of Kezar’s R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer.\n\nIn addition, Craig S. Lammert, M.D., Assistant Professor of Medicine at Indiana University School of Medicine and Executive Director of the Autoimmune Hepatitis Association, will present on autoimmune hepatitis (AIH), the unmet need, and the treatment landscape. PORTOLA, a signal seeking study of zetomipzomib in AIH, initiated in the first quarter 2023.\n\nThe presentation will be followed by a Q&A session.\n\nPresenters:\n\n\nJohn Fowler, Chief Executive Officer, Co-Founder\n\n\nNoreen Roth Henig, M.D., Chief Medical Officer\n\n\nCraig S. Lammert, M.D., Assistant Professor of Medicine at Indiana University School of Medicine, and Executive Director of the Autoimmune Hepatitis Association\n\n\nNeel Anand, D. Phil. (Ph.D.), Senior Vice President, Research and Drug Discovery\n\n\nTo register for this event, please visit the Events & Presentations page of Kezar’s website. On the day of the event, a live webcast and conference call will be accessible from the Events & Presentations page of Kezar’s website. Additionally, a replay of the event will be available for 90 days following the presentation.\n\nAbout Zetomipzomib\n\nZetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 and Phase 2 clinical trials provide evidence th...